Literature DB >> 15357514

Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain.

Billy R Martin1, Jenny L Wiley.   

Abstract

Many patients with life-threatening diseases such as cancer experience severe symptoms that compromise their health status and deny them quality of life. Patients with cancer often experience cachexia, pain, and depression,which translate into an unacceptable quality of life. The discovery of the endocannabinoid system has led to a renewed interest in the use of cannabinoids for the management of nausea, vomiting, and weight loss arising either from cancer or the agents used to treat cancer. The endocannabinoid system has been found to be a key modulator of systems involved in pain perception, emesis, and reward pathways. As such, it represents a target for development of new medications for controlling the symptoms associated with cancer. Although the cannabinoid receptor agonist tetrahydrocannabinol and one of its analogs are currently the only agents approved for clinical use, efforts are under way to devise other strategies for activating the endocannabinoid system for therapeutic uses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357514

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


  18 in total

Review 1.  Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway.

Authors:  Carlos Camps; Vega Iranzo; Roy M Bremnes; Rafael Sirera
Journal:  Support Care Cancer       Date:  2006-07-04       Impact factor: 3.603

Review 2.  Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.

Authors:  Cecilia J Sorensen; Kristen DeSanto; Laura Borgelt; Kristina T Phillips; Andrew A Monte
Journal:  J Med Toxicol       Date:  2016-12-20

3.  Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.

Authors:  Kimberly R Warren; Robert W Buchanan; Stephanie Feldman; Robert R Conley; Jared Linthicum; Mary Patricia Ball; Fang Liu; Robert P McMahon; David A Gorelick; Marilyn A Huestis; Deanna L Kelly
Journal:  J Clin Psychopharmacol       Date:  2013-02       Impact factor: 3.153

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Nutritional interventions for cancer-induced cachexia.

Authors:  Norleena P Gullett; Vera C Mazurak; Gautam Hebbar; Thomas R Ziegler
Journal:  Curr Probl Cancer       Date:  2011 Mar-Apr       Impact factor: 3.187

6.  Evidence for the putative cannabinoid receptor (GPR55)-mediated inhibitory effects on intestinal contractility in mice.

Authors:  Gracious R Ross; Aron Lichtman; William L Dewey; Hamid I Akbarali
Journal:  Pharmacology       Date:  2012-06-28       Impact factor: 2.547

7.  Molecules Acting on CB1 Receptor and their Effects on Morphine Withdrawal In Vitro.

Authors:  Anna Capasso; Chiara Gallo
Journal:  Open Biochem J       Date:  2009-12-11

Review 8.  Chemotherapy-induced nausea and vomiting: optimizing prevention and management.

Authors:  Kamakshi V Rao; Aimee Faso
Journal:  Am Health Drug Benefits       Date:  2012-07

Review 9.  Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.

Authors:  Rudolph M Navari
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes.

Authors:  Keun-Hang Yang; Sehamuddin Galadari; Dmytro Isaev; Georg Petroianu; Toni S Shippenberg; Murat Oz
Journal:  J Pharmacol Exp Ther       Date:  2010-02-16       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.